100 related articles for article (PubMed ID: 14687705)
1. Enhancement of a human immunodeficiency virus env DNA vaccine using a novel polycationic nanoparticle formulation.
Locher CP; Putnam D; Langer R; Witt SA; Ashlock BM; Levy JA
Immunol Lett; 2003 Dec; 90(2-3):67-70. PubMed ID: 14687705
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of genetic immunization adjuvants to improve the effectiveness of a human immunodeficiency virus type 2 (HIV-2) envelope DNA vaccine.
Locher CP; Witt SA; Ashlock BM; Levy JA
DNA Cell Biol; 2004 Feb; 23(2):107-10. PubMed ID: 15000750
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of antibody responses to an HIV-2 DNA envelope vaccine using an expression vector containing a constitutive transport element.
Locher CP; Witt SA; Ashlock BM; Levy JA
DNA Cell Biol; 2002 Aug; 21(8):581-6. PubMed ID: 12215261
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity testing of a novel engineered HIV-1 envelope gp140 DNA vaccine construct.
Kumar S; Yan J; Muthumani K; Ramanathan MP; Yoon H; Pavlakis GN; Felber BK; Sidhu M; Boyer JD; Weiner DB
DNA Cell Biol; 2006 Jul; 25(7):383-92. PubMed ID: 16848679
[TBL] [Abstract][Full Text] [Related]
5. Increased level and longevity of protective immune responses induced by DNA vaccine expressing the HIV-1 Env glycoprotein when combined with IL-21 and IL-15 gene delivery.
Bolesta E; Kowalczyk A; Wierzbicki A; Eppolito C; Kaneko Y; Takiguchi M; Stamatatos L; Shrikant PA; Kozbor D
J Immunol; 2006 Jul; 177(1):177-91. PubMed ID: 16785513
[TBL] [Abstract][Full Text] [Related]
6. Cross-subtype T-cell immune responses induced by a human immunodeficiency virus type 1 group m consensus env immunogen.
Weaver EA; Lu Z; Camacho ZT; Moukdar F; Liao HX; Ma BJ; Muldoon M; Theiler J; Nabel GJ; Letvin NL; Korber BT; Hahn BH; Haynes BF; Gao F
J Virol; 2006 Jul; 80(14):6745-56. PubMed ID: 16809280
[TBL] [Abstract][Full Text] [Related]
7. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
[TBL] [Abstract][Full Text] [Related]
8. Development of V2-deleted trimeric envelope vaccine candidates from human immunodeficiency virus type 1 (HIV-1) subtypes B and C.
Barnett SW; Srivastava IK; Ulmer JB; Donnelly JJ; Rappuoli R
Microbes Infect; 2005 Nov; 7(14):1386-91. PubMed ID: 16275150
[TBL] [Abstract][Full Text] [Related]
9. HIV-1 Envgp140 trimers elicit neutralizing antibodies without efficient induction of conformational antibodies.
Bower JF; Li Y; Wyatt R; Ross TM
Vaccine; 2006 Jun; 24(26):5442-51. PubMed ID: 16621193
[TBL] [Abstract][Full Text] [Related]
10. Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization.
Chakrabarti BK; Kong WP; Wu BY; Yang ZY; Friborg J; Ling X; King SR; Montefiori DC; Nabel GJ
J Virol; 2002 Jun; 76(11):5357-68. PubMed ID: 11991964
[TBL] [Abstract][Full Text] [Related]
11. DNA vaccination of macaques by a full genome HIV-1 plasmid which produces noninfectious virus particles.
Akahata W; Ido E; Shimada T; Katsuyama K; Yamamoto H; Uesaka H; Ui M; Kuwata T; Takahashi H; Hayami M
Virology; 2000 Sep; 275(1):116-24. PubMed ID: 11017793
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant action of murine IL-2/Ig plasmid after intramuscular immunization with Indian HIV-1 subtype C recombinant env.gp 120 construct.
Aggarwal P; Kumar S; Vajpayee M; Seth P
Viral Immunol; 2005; 18(4):649-56. PubMed ID: 16359231
[TBL] [Abstract][Full Text] [Related]
13. Increased expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 gag gene.
zur Megede J; Chen MC; Doe B; Schaefer M; Greer CE; Selby M; Otten GR; Barnett SW
J Virol; 2000 Mar; 74(6):2628-35. PubMed ID: 10684277
[TBL] [Abstract][Full Text] [Related]
14. A DNA vaccine containing inverted terminal repeats from adeno-associated virus increases immunity to HIV.
Xin KQ; Ooki T; Jounai N; Mizukami H; Hamajima K; Kojima Y; Ohba K; Toda Y; Hirai S; Klinman DM; Ozawa K; Okuda K
J Gene Med; 2003 May; 5(5):438-45. PubMed ID: 12731092
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of immune responses to an HIV env DNA vaccine by a C-terminal segment of listeriolysin O.
Bu Z; Ye L; Skeen MJ; Ziegler HK; Compans RW; Yang C
AIDS Res Hum Retroviruses; 2003 May; 19(5):409-20. PubMed ID: 12803999
[TBL] [Abstract][Full Text] [Related]
16. Use of a new dual-antigen enzyme-linked immunosorbent assay to detect and characterize the human antibody response to the human immunodeficiency virus type 2 envelope gp125 and gp36 glycoproteins.
Marcelino JM; Barroso H; Gonçalves F; Silva SM; Novo C; Gomes P; Camacho R; Taveira N
J Clin Microbiol; 2006 Feb; 44(2):607-11. PubMed ID: 16455923
[TBL] [Abstract][Full Text] [Related]
17. [Study on Cellular Immune Responses of DNA Vaccine, rAd5 and rMVA Expressing SIV Gag/Env Gene Combined Immunization in Mice].
He X; Chen D; Wang W; Xu K; Zeng Y; Feng X
Bing Du Xue Bao; 2016 Mar; 32(2):170-8. PubMed ID: 27396160
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity of HIV-1 Env and Gag in baboons using a DNA prime/protein boost regimen.
Leung L; Srivastava IK; Kan E; Legg H; Sun Y; Greer C; Montefiori DC; zur Megede J; Barnett SW
AIDS; 2004 Apr; 18(7):991-1001. PubMed ID: 15096801
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity of DNA vaccines expressing human immunodeficiency virus type 1 envelope glycoprotein with and without deletions in the V1/2 and V3 regions.
Lu S; Wyatt R; Richmond JF; Mustafa F; Wang S; Weng J; Montefiori DC; Sodroski J; Robinson HL
AIDS Res Hum Retroviruses; 1998 Jan; 14(2):151-5. PubMed ID: 9462925
[TBL] [Abstract][Full Text] [Related]
20. HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates.
García-Arriaza J; Perdiguero B; Heeney JL; Seaman MS; Montefiori DC; Yates NL; Tomaras GD; Ferrari G; Foulds KE; Roederer M; Self SG; Borate B; Gottardo R; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo AD; Weiss DE; Lee C; Kibler KV; Jacobs BL; Wagner R; Ding S; Pantaleo G; Esteban M
J Virol; 2017 May; 91(9):. PubMed ID: 28179536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
